Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07060066 · ClinicalTrials.gov registry record · NA
Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia
A NA study of Schizophrenia and Related Disorders, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07060066: Recruiting NA study of Schizophrenia and Related Disorders, sponsored by The University of Texas Health Science Center, Houston.
NCT07060066 is a NA study of Schizophrenia and Related Disorders that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 120 participants, below the 251-participant average among 4 other Schizophrenia and Related Disorders trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07060066, a NA study of Schizophrenia and Related Disorders, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia. Schizophrenia patients with depressive symptoms will be exposed to rTMS to improve their symptoms.
Primary Outcome
rsFC values will be reported as a Z-score with a range of -1 to 1, with greater absolute values indicating stronger brain connectivity.
Conditions Studied
Interventions
- DEVICE Active rTMS stimulation
- DEVICE Sham rTMS stimulation
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2030-06-01 |
| Phase | NA |
What NCT07060066 shows while recruiting
NCT07060066 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 251-participant average among 4 other Schizophrenia and Related Disorders trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Schizophrenia and Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Active rTMS stimulation is the first listed.
NCT07060066 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07060066 about?
NCT07060066 is a clinical study titled "Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia". The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia. Schizophrenia patients with depressive symptoms will be exposed to rTMS to improve their symptoms.
What is the current status of trial NCT07060066?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-05-21. Estimated completion is 2030-06-01.
What conditions does trial NCT07060066 study?
This clinical trial studies the following conditions: Schizophrenia and Related Disorders.
What interventions are being tested in trial NCT07060066?
The interventions under investigation include: Active rTMS stimulation (DEVICE), Sham rTMS stimulation (DEVICE).
Who is sponsoring clinical trial NCT07060066?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07060066 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia and Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment
RECRUITING · NA
-
SPARK Healthy Sleep
RECRUITING · NA
-
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
RECRUITING · Phase 2
-
Social Isolation and Aging in Schizophrenia
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI